{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T09:11:51Z","timestamp":1770023511822,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013327","name":"Lundbeck","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s40122-023-00534-w","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T12:15:38Z","timestamp":1687436138000},"page":"1283-1291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Managing Migraine: Medication Overuse Headache and Treatment with Eptinezumab"],"prefix":"10.1007","volume":"12","author":[{"given":"Nicole","family":"Limberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"issue":"1","key":"534_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s10194-018-0875-x","volume":"19","author":"N Vandenbussche","year":"2018","unstructured":"Vandenbussche N, Laterza D, Lisicki M, Lloyd J, Lupi C, Tischler H, et al. Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain. 2018;19(1):50.","journal-title":"J Headache Pain"},{"key":"534_CR2","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"534_CR3","doi-asserted-by":"crossref","unstructured":"Diener HC, Marmura MJ, Tepper SJ, Cowan R, Starling AJ, Diamond ML, et al. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication\u2010overuse headache: subgroup analysis of PROMISE-2. Headache. 2021;61(1):125\u201336.","DOI":"10.1111\/head.14036"},{"key":"534_CR4","unstructured":"Therapeutic Goods Administration. Eptinezumab (Vyepti) concentrated injection product information Canberra: Commonwealth Government of Australia; 2021. https:\/\/www.ebs.tga.gov.au."},{"issue":"10","key":"534_CR5","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrneurol.2010.127","volume":"6","author":"TW Ho","year":"2010","unstructured":"Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010;6(10):573\u201382.","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"534_CR6","doi-asserted-by":"publisher","first-page":"915","DOI":"10.31128\/AJGP-01-21-5807","volume":"50","author":"JC Ray","year":"2021","unstructured":"Ray JC, Macindoe C, Ginevra M, Hutton EJ. The state of migraine: an update on current and emerging treatments. Aust J Gen Pract. 2021;50(12):915\u201321.","journal-title":"Aust J Gen Pract"},{"issue":"5","key":"534_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40263-021-00818-9","volume":"35","author":"C Sun-Edelstein","year":"2021","unstructured":"Sun-Edelstein C, Rapoport AM, Rattanawong W, Srikiatkhachorn A. The evolution of medication overuse headache: history, pathophysiology and clinical update. CNS Drugs. 2021;35(5):545\u201365.","journal-title":"CNS Drugs"},{"issue":"5","key":"534_CR8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.18773\/austprescr.2020.047","volume":"43","author":"B Jenkins","year":"2020","unstructured":"Jenkins B. Migraine management. Aust Prescr. 2020;43(5):148\u201351.","journal-title":"Aust Prescr"},{"issue":"7","key":"534_CR9","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/ene.14268","volume":"27","author":"HC Diener","year":"2020","unstructured":"Diener HC, Antonaci F, Braschinsky M, Evers S, Jensen R, Lainez M, et al. European Academy of Neurology guideline on the management of medication-overuse headache. Eur J Neurol. 2020;27(7):1102\u201316.","journal-title":"Eur J Neurol"},{"key":"534_CR10","doi-asserted-by":"crossref","unstructured":"Goadsby P. The \u2018Act When Mild\u2019 (AwM) Study: a step forward in our understanding of early treatment in acute migraine. Cephalalgia. 2008;28(2_suppl):36\u201341.","DOI":"10.1111\/j.1468-2982.2008.01689.x"},{"issue":"7","key":"534_CR11","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","volume":"21","author":"M Ashina","year":"2022","unstructured":"Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK, et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022;21(7):597\u2013607.","journal-title":"Lancet Neurol"},{"issue":"10","key":"534_CR12","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1111\/head.14007","volume":"60","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S. Eptinezumab demonstrated efficacy in sustained prevention of episodic and chronic migraine beginning on day 1 after dosing. Headache. 2020;60(10):2220\u201331.","journal-title":"Headache"},{"issue":"1","key":"534_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/head.14036","volume":"61","author":"HC Diener","year":"2021","unstructured":"Diener HC, Marmura MJ, Tepper SJ, Cowan R, Starling AJ, Diamond ML, et al. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: subgroup analysis of PROMISE-2. Headache. 2021;61(1):125\u201336.","journal-title":"Headache"},{"issue":"4\u20135","key":"534_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/03331024211048765","volume":"42","author":"LH Overeem","year":"2022","unstructured":"Overeem LH, Peikert A, Hofacker MD, Kamm K, Ruscheweyh R, Gendolla A, et al. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalalgia. 2022;42(4\u20135):291\u2013301.","journal-title":"Cephalalgia"},{"key":"534_CR15","doi-asserted-by":"crossref","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789\u2013858.","DOI":"10.1016\/S0140-6736(18)32279-7"},{"key":"534_CR16","unstructured":"Deloitte Access Economics. Migraine in Australia whitepaper. Canberra: Deloitte Access Economics Report. 2018."},{"issue":"1","key":"534_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12883-021-02123-w","volume":"21","author":"D Kudrow","year":"2021","unstructured":"Kudrow D, Cady RK, Allan B, Pederson SM, Hirman J, Mehta LR, et al. Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC Neurol. 2021;21(1):126.","journal-title":"BMC Neurol"},{"key":"534_CR18","doi-asserted-by":"crossref","unstructured":"Goadsby PJ, Barbanti P, Lambru G, Ettrup A, Christoffersen CL, Josiassen MK, et al. Eptinezumab improved patient-reported outcomes and quality of life in patients with migraine and prior preventive treatment failures. Eur J Neurol. 2022;20:1089\u20131098.","DOI":"10.1111\/ene.15670"}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-023-00534-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-023-00534-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-023-00534-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T13:20:04Z","timestamp":1692710404000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-023-00534-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["534"],"URL":"https:\/\/doi.org\/10.1007\/s40122-023-00534-w","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,22]]},"assertion":[{"value":"1 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}